TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
RDNT

RadNet Inc

Healthcare · Diagnostics & Research

76.00$ -2.3% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

RadNet Inc (RDNT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 2,040 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement RDNT
Line item 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
57 67 59 72 88 112 139 140 137 146 161 425 502 524 549 620 647 703 718 810 885 922 975 1,154 1,072 1,315 1,430 1,617 1,830 2,040
59 62 78 105 106 106 109 120 331 384 398 421 478 543 599 603 708 776 802 868 1,000 966 1,123 1,264 1,395 1,581 1,949
57 67 59 13 26 34 34 34 31 37 41 95 118 127 128 142 104 104 115 101 109 120 108 154 106 192 166 221 249 91
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3
3.1 2.6 4.0 7.2 4.9 3.9 5.6 3.9 27 31 0.7 0.8 1.4 2.7 0.8 1.2 0.7 2.9 1.8 869 1,001 970 1,124 1,265
58 74 75 11 11 15 22 22 22 23 24 73 85 87 88 94 58 59 59 61 67 67 73 85 70 109 119 123 144 1,978
-1.8 -7.7 -17 2.4 15 19 11 12 9.8 14 16 21 33 39 38 51 45 44 53 39 38 50 31 70 36 83 46 99 105 91
7.9 9.8 9.3 0.0 13 14 17 18 17 17 20 44 52 49 48 53 54 46 43 42 43 41 43 48 46 49 51 64 80 70
-0.8 7.1 -20 0.4 15 9.2 -5.2 -5.4 -9.3 -3.1 -6.9 -18 -19 -10 -20 2.9 -2.1 5.9 3.7 15 12 26 39 30 -0.9 59 43 39 45 32
6.5 -6.3 13 11 12 -5.1 17 0.0 5.2 17 17 0.3 0.2 0.4 0.6 0.8 -60 3.5 2.0 6.0 4.4 24 0.4 6.2 0.9 15 9.4 8.5 6.0 15
-8.4 -0.7 -29 -9.0 2.6 15 -5.6 -2.3 -15 -3.1 -6.9 -18 -13 -2.3 -13 7.2 65 2.1 1.4 7.7 7.2 0.1 32 15 -15 25 11 3.0 2.8 -19
4.2 1.8 -7.9 9.9 23 29 25 29 29 30 33 68 87 85 81 106 109 104 115 117 109 120 108 225 200 278 279 293 263 254

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?